WO2014182813A1 - Antimicrobial compositions containing carvacrol and thymol - Google Patents

Antimicrobial compositions containing carvacrol and thymol Download PDF

Info

Publication number
WO2014182813A1
WO2014182813A1 PCT/US2014/037148 US2014037148W WO2014182813A1 WO 2014182813 A1 WO2014182813 A1 WO 2014182813A1 US 2014037148 W US2014037148 W US 2014037148W WO 2014182813 A1 WO2014182813 A1 WO 2014182813A1
Authority
WO
WIPO (PCT)
Prior art keywords
carvacrol
thymol
oil
ppm
oregano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/037148
Other languages
French (fr)
Inventor
Sally Moore
Mitchell POSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Industries Inc
Original Assignee
Kemin Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Industries Inc filed Critical Kemin Industries Inc
Priority to CN201480026108.6A priority Critical patent/CN105357971A/en
Priority to EP14794324.5A priority patent/EP2993985A4/en
Priority to BR112015027837A priority patent/BR112015027837A2/en
Publication of WO2014182813A1 publication Critical patent/WO2014182813A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08Oxygen or sulfur directly attached to an aromatic ring system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08Magnoliopsida [dicotyledons]
    • A01N65/22Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint

Definitions

  • the present invention relates generally to compounds having antimicrobial properties and, more specifically to the antimicrobial properties of carvacrol and thymol.
  • Carvacrol and thymol are two components of oregano oil that confer antimicrobial activity against both gram negative (G-) and gram positive (G+) bacteria and the effectiveness of these compounds is well documented in the literature (Helender, I., H-L. Alakomi, K. Latva-Kala, T. Mattila-Sandholm, I. Pol, E. Smid, L. Gorris and A. von Wright. 1998. Characterization of the action of selected essential oil components on gram negative bacteria. J. Agric. Food Chem. 46:3590-3595; Sokovic, M., P. Marin, D. Brkic and L. van Griensven. 2007. Chemical composition and antibacterial activity of essential oils of ten aromatic plants against human pathogenic bacteria. Food:Global Science Books; Derwich, E., Z. Benziane, A. Manar, A. Boukir and R. Taouil. 2010. Phytochemical analysis and in vitro antibacterial activity of the essential oil of Origanum vulgar e from
  • Carvacrol and thymol are structural isomers possessing a hydroxyl group at different positions on the phenolic ring.
  • antimicrobial activity of both molecules is similar and does not appear to be affected by the position of the hydroxyl group (Rasooli, 2007).
  • the levels of carvacrol and thymol inhibitive to microbial growth can vary depending on the challenge organism and the test methodology (Rasooli, 2007). Consequently, the minimum inhibitory concentrations (MIC) effective to inhibit the growth of selected microorganisms were determined in a micro titer plate assay using carvacrol and thymol standards. Micro titer plate assays are commonly used and convenient due to the low volume of test material required, easy preparation of replicate wells, ability to screen multiple treatment levels and the ability to combine antimicrobials for observation of synergistic, additive or antagonistic effects (Rasooli, 2007).
  • Kemin's Specialty Crop Improvement (SCI) program is developing oregano plant lines that contain >5 carvacrol (dry weight basis) and >3.8 thymol (dry weight basis). The oils extracted from these plants will be used to develop a new antimicrobial product for animal feed and blended in a proprietary formulation making a unique product for SCI.
  • MICs minimum inhibitory concentrations
  • carvacrol and thymol in the essential oils extracted from oregano plants were determined via microtiter plate assays. Either 3x3 or 4x4 matrices were used to evaluate the antimicrobial effects of carvacrol and thymol individually or in combinations. Both carvacrol (98%) and thymol (99.5%) inhibited the growth of both S. Enteritidis and E. coli at levels greater than 125 ppm but less than 250 ppm. Carvacrol in the extracted oil at either 80% or 68% required >175 or >200 ppm carvacrol, respectively, to inhibit both organisms.
  • Thymol was a constant concentration in the oil at 70% and required >200 ppm to inhibit the same two organisms.
  • the work presented here supports combinations of the oil containing 68% or 80% carvacrol and the oil containing 70% thymol resulting in a 2: 1 or 1:2 carvacrol: thymol ratio were effective in the growth inhibition of S. Enteritidis and E. coli.
  • Figs. 1A-1C are charts of the kinetic growth curves showing the effects of the standards - C (carvacrol), T (thymol) or C:T (carvacrokthymol)- on S. Enteritidis (A), E. coli (B) and Bacillus subtilis strain PB6 (C); refer to Table 1 for the formulations.
  • Figs. 2A and 2B are charts showing the endpoint growth curves showing the effects of the standards - C, T or C:T - on S. Enteritidis (A) and PB6 (B); refer to Table 2 for the formulations.
  • Figs. 3A and 3B are charts of the kinetic growth curves showing the effects of treatment
  • Figs. 4A-4D are charts of the kinetic growth curves showing the effects of treatment - HC, HT or HC:HT oils. Description of the Invention
  • Oregano plants have long been recognized as a source of carvacrol and thymol.
  • Accessions of oregano vary widely in the amounts of carvacrol and thymol produced by the plants. Our research has shown that some accessions produce carvacrol predominantly over thymol while other accessions produce thymol predominantly over carvacrol.
  • Conventional plant breeding techniques were used to produce clonal lines of oregano that had greater than 20 mg/g carvacrol, at 50 mg/g and up to at least 69.7 g/mg carvacrol on a dry matter basis. These high carvacrol lines typically had low levels of thymol, ranging from between a ratio of carvacrol to thymol of 10: 1, 50: 1 and up to at least 713: 1.
  • Inhibitory levels were first determined using carvacrol and thymol standards.
  • HC:HT oils extracted from plants grown internally were blended achieving the targeted levels of carvacrol and thymol. Further inhibition assays were conducted to verify the effectiveness of the oil blend.
  • Thymol and carvacrol were purchased from Sigma- Aldrich Chemical
  • Oregano oil The oregano oil used in these experiments was extracted from plants grown internally. Plant lines containing high carvacrol levels (HC) were identified. Specifically, the hich carvacrol strain KI-Ovl750, which is the subject of United States Patent Application Serial No. 61/855,067, filed May 7, 2013 (which is incorporated herein in its entirety by this reference), was developed. The oil extracted from the HC plant lines was combined and resulted in a carvacrol level of 67.7% (thymol level of 0.93%). Plant lines containing high thymol levels (HT) were identified. Specifically, the high thymol strain KI-Ovl850, which is the subject of United States Patent Application Serial No. 61/855,068, filed May 7, 2013 (which is
  • Treatment Preparation - standards (Tables 1 and 2).
  • Stock solutions of 1000 ppm each of carvacrol and thymol standards were prepared in sterile TSB to which 0.1% agar was added for stabilization of the oil: water emulsion (Rasooli et al., 2007; Burt, S. and R. Reinders. 2003. Antibacterial activity of selected plant essential oils against Escherichia coli 0157:H7. Letters Appl. Microbiol. 36: 162-167). Subsequent dilutions and/or combinations of the standard stock solutions were prepared in TSB to achieve the targeted inclusion level of each molecule.
  • Blended oils The extracted oils were blended in a 2: 1 ratio (v/v) of HC:HT.
  • Microtiter Plate Assay The efficacy of carvacrol and thymol in the inhibition of microbial growth was evaluated in a microtiter plate assay measuring the optical density at 620 nm using an Optimax microtiter plate reader (Molecular Devices, Sunnyvale, CA). Plates were read kinetically (aerobic organisms) or endpoint (anaerobic organisms) over 20-24 h while maintaining temperature at 35 °C. All results reflect the average optical density measurements of four microtiter wells.
  • a 100 uL aliquot of a test organism (1.0E+06 cfu/mL) in sterile saline and a 100 ⁇ ⁇ aliquot of experimental treatment were dispensed into individual microtiter plate wells.
  • Treatments prepared in TSB were used for E. coli, S. Enteritidis and PB6 while treatments prepared in MRS broth were used for L. johnsonii Dl 15.
  • Positive controls consisted of 100 ⁇ ⁇ of test organism in sterile saline and 100 ⁇ ⁇ of sterile TSB or MRS.
  • Negative controls were made of 100 ⁇ ⁇ of sterile TSB or MRS and 100 ⁇ ⁇ of sterile saline (no organisms).
  • microorganisms were evaluated through several formulation matrices designed to assess the individual molecules as well as combinations of the molecules. Initially, thirteen formulations were prepared according to the incomplete 4x4 matrix design in Table 1 using 0, 125, 250 and 500 ppm each of carvacrol standard and thymol standard to evaluate the inhibitory activity toward selected microorganisms. In all instances formulas are noted as Fl, F2, etc. Subsequent matrices were designed to fine-tune inclusion levels of carvacrol and thymol.
  • 125 F13 F14 F15 F16 A third matrix of 9 formulas (Table 3) was created using oil from oregano plants grown by SCI and extracted on site. The treatment levels chosen were based on activity levels observed in previous experiments using carvacrol and thymol standards. For example, if 125 ppm of a 98% carvacrol standard was sufficient to inhibit the growth of a selected bacteria, then 180 ppm of extracted oil containing 68% carvacrol would be required to observe the same effect.
  • Table 3 A 3x3 matrix design of 9 combinations using oil extracted from oregano plants harvested by SCI.
  • the HC oregano plants contained 68% carvacrol while the HT oregano plants contained 70% thymol
  • a fourth matrix of 9 formulations was prepared using SCI oregano oil of 68% carvacrol but supplemented with carvacrol standard to achieve an 80% carvacrol level.
  • the HT oil was used as extracted. Treatment levels were targeted based on previous results.
  • Table 4 A 3x3 matrix design of 9 formulations using oil extracted from SCI oregano plants where the HC oil was supplemented with carvacrol standard to achieve an 80% carvacrol level
  • the carvacrol level in the SCI extracted oil was increased from 68% to 80% using carvacrol standard and verified via HPLC analysis.
  • the thymol level in the extracted oil was maintained at 70%.
  • treatment levels were selected and inhibition of microorganisms was evaluated.
  • Figs. 4A-4D are charts showing the kinetic growth curves showing the effects of treatment -HC, HT or HC:HT oils - using oregano oil extracted from plants grown by SCI.
  • the level of carvacrol in the extracted HC oil was increased to 80%.
  • the effects to the growth of S. Enteritidis and L. johnsonii Dl 15 are shown in graphs A and B, respectively.
  • Graphs C and D reflect the effect of treatment on E. coli.
  • One well in each of series F5 and F7 showed growth and could have been inadvertent contamination or variability in the inoculum used in the wells.
  • Graph C includes the readings from all 4 wells while graph D does not include the well with growth. While there is minimal difference, this could be indicative of the "borderline" treatment level of F5.
  • the carvacrol level is 68%.
  • Carvacrol and thymol were found to be equally effective in the inhibition of E. coli and S. Enteritidis at the levels tested. As expected, higher concentrations of either of these molecules resulted in lower effective treatment levels. The absolute endpoint for efficacy of each molecule was not determined as the focus was to determine the lowest inclusion levels of each molecule in a blended product. The blended oils showed the most efficacy at a 2: 1 HC oil:HT oil or HT oil: HC oil ratio. This was also observed when using carvacrol and thymol standards. Carvacrol and thymol are structural isomers displaying similar inhibitory activity (Michiels, et al., 2007).
  • Enteritidis are higher than that for B. subtilis PB6 (G+).
  • Gram (-) organisms are more tolerant due to the hydrophilic outer membrane which blocks entry of the hydrophobic essential oil (Ait-Ouazzou, et al., 2011).
  • Bacillus species were especially sensitive to thyme essential oil (Ait-Ouazzou, et al., 2011). While 125 ppm inhibited the growth of PB6 as noted in Fig 1, it was not sufficient to inhibit growth as noted in Fig 2. This may be indicative of a borderline treatment effect.
  • Work conducted by J. Michiels, et.al reported that carvacrol and thymol inhibited the growth of E.
  • the oregano oil available on the market today typically contains >60% carvacrol but thymol levels are 4% or less.
  • a blended oil product containing high levels of both carvacrol and thymol will provide an additional "hurdle" for the pathogens to overcome.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pest Control & Pesticides (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates generally to compounds having antimicrobial properties and, more specifically to the antimicrobial properties of carvacrol and thymol. Compositions having a combination of carvacrol and thymol are found to have synergistic antimicrobial activity against feed pathogens. Oregano plant lines that contain >5% carvacrol (dry weight basis) and >3.8% thymol (dry weight basis) are used to develop a new antimicrobial product for animal feed.

Description

ANTIMICROBIAL COMPOSITIONS CONTAINING CARVACROL AND THYMOL
[0001] This application claims priority to United States Patent Application Serial No.
61/820,455, filed May 7, 2013, and incorporates the same herein in its entirety by this reference.
Background of the Invention
[0002] The present invention relates generally to compounds having antimicrobial properties and, more specifically to the antimicrobial properties of carvacrol and thymol.
[0003] Antibiotic use in animal production worldwide is being challenged more than ever, and in many countries the use of certain antibiotics has been banned (Windisch, W., K. Schedle, C. Plitzner and A. Kroismayr. 2008. Use of phyto genie products as feed additives for swine and poultry. J. Anim. Sci. 86 (E Suppl): E140-E148). While many synthetic molecules are effective against foodborne pathogens, the use of "natural" molecules such as those derived from plants and probiotics are gaining attention as alternatives to antibiotic use. Carvacrol and thymol are two components of oregano oil that confer antimicrobial activity against both gram negative (G-) and gram positive (G+) bacteria and the effectiveness of these compounds is well documented in the literature (Helender, I., H-L. Alakomi, K. Latva-Kala, T. Mattila-Sandholm, I. Pol, E. Smid, L. Gorris and A. von Wright. 1998. Characterization of the action of selected essential oil components on gram negative bacteria. J. Agric. Food Chem. 46:3590-3595; Sokovic, M., P. Marin, D. Brkic and L. van Griensven. 2007. Chemical composition and antibacterial activity of essential oils of ten aromatic plants against human pathogenic bacteria. Food:Global Science Books; Derwich, E., Z. Benziane, A. Manar, A. Boukir and R. Taouil. 2010. Phytochemical analysis and in vitro antibacterial activity of the essential oil of Origanum vulgar e from
Morocco. Am-Euras. J. Sci. Res. 5 (2): 120-129; Michiels, J., J. Missotten, D. Fremaut, S. De Smet and N. Dierick. 2007. In vitro dose-response of carvacrol, thymol, eugenol and trans- cinnamaldehyde and interaction of combinations for the antibicorbial activity against the pig gut flora. Livestock Science 109: 157-160; Bajpai, V., K-H. Baek, and S. Kang. 2011. Control of Salmonella in foods by using essential oils: a review. Food Research International. Article in Press). The accepted mode of action for essential oils is the hydrophobicity of the oils which enables them to penetrate the outer cell membrane of gram-negative bacteria disrupting the membrane structure and causing ion leakage (Windisch et al., 2008; Rasooli, I., 2007. Food preservation - a biopreservative approach. Food. Global Science Books; Guarda, A. J. Rubilar, J. Miltz and M. Galotto. 2011. The antimicrobial activity of microencapsulated thymol and carvacrol. Int. J. Food Microbiol. 146: 144-1580). It is documented that essential oils
demonstrating the highest degree of microbial inhibition contain high levels of phenolic compounds such as carvacrol and thymol (Rasooli, 2007). Carvacrol and thymol are structural isomers possessing a hydroxyl group at different positions on the phenolic ring. The
antimicrobial activity of both molecules is similar and does not appear to be affected by the position of the hydroxyl group (Rasooli, 2007).
Figure imgf000003_0001
Carvacrol Thymol
[0004] The levels of carvacrol and thymol inhibitive to microbial growth can vary depending on the challenge organism and the test methodology (Rasooli, 2007). Consequently, the minimum inhibitory concentrations (MIC) effective to inhibit the growth of selected microorganisms were determined in a micro titer plate assay using carvacrol and thymol standards. Micro titer plate assays are commonly used and convenient due to the low volume of test material required, easy preparation of replicate wells, ability to screen multiple treatment levels and the ability to combine antimicrobials for observation of synergistic, additive or antagonistic effects (Rasooli, 2007).
[0005] Several competitive products are currently being marketed by Ralco, Meriden, DSM, Biomin and Delacon. Kemin's Specialty Crop Improvement (SCI) program is developing oregano plant lines that contain >5 carvacrol (dry weight basis) and >3.8 thymol (dry weight basis). The oils extracted from these plants will be used to develop a new antimicrobial product for animal feed and blended in a proprietary formulation making a unique product for
introduction into the feed additive market. Summary of the Invention
[0006] The primary objective of this work was to determine the most efficacious blend of oils high in carvacrol and thymol that would result in the inhibition of selected food safety pathogens
- E. coli and Salmonella Enteritidis . The effect of treatment to beneficial gut bacteria such as lactic acid bacteria as well as Bacillus subtilis PB6 - the active microbial in CLOSTAT® brand Dry Direct-Fed Microbial (Kemin Industries, Des Moines, Iowa) - was also determined.
[0007] The minimum inhibitory concentrations (MICs) of carvacrol and thymol in the essential oils extracted from oregano plants were determined via microtiter plate assays. Either 3x3 or 4x4 matrices were used to evaluate the antimicrobial effects of carvacrol and thymol individually or in combinations. Both carvacrol (98%) and thymol (99.5%) inhibited the growth of both S. Enteritidis and E. coli at levels greater than 125 ppm but less than 250 ppm. Carvacrol in the extracted oil at either 80% or 68% required >175 or >200 ppm carvacrol, respectively, to inhibit both organisms. Thymol was a constant concentration in the oil at 70% and required >200 ppm to inhibit the same two organisms. The work presented here supports combinations of the oil containing 68% or 80% carvacrol and the oil containing 70% thymol resulting in a 2: 1 or 1:2 carvacrol: thymol ratio were effective in the growth inhibition of S. Enteritidis and E. coli.
Brief Description of the Figures
[0008] Figs. 1A-1C are charts of the kinetic growth curves showing the effects of the standards - C (carvacrol), T (thymol) or C:T (carvacrokthymol)- on S. Enteritidis (A), E. coli (B) and Bacillus subtilis strain PB6 (C); refer to Table 1 for the formulations.
[0009] Figs. 2A and 2B are charts showing the endpoint growth curves showing the effects of the standards - C, T or C:T - on S. Enteritidis (A) and PB6 (B); refer to Table 2 for the formulations.
[0010] Figs. 3A and 3B are charts of the kinetic growth curves showing the effects of treatment
- HC (high carvacrol), HT (high thymol) or HC:HT (high carvacrokthymol) - on E. coli (A) and PB6 (B) using oregano oil extracted from plants. The treatment levels of the extracted oils were adjusted to match previous levels when using the carvacrol and thymol standards; refer to Table 3 for the treatment formulations.
[0011] Figs. 4A-4D are charts of the kinetic growth curves showing the effects of treatment - HC, HT or HC:HT oils. Description of the Invention
[0012] Oregano plants have long been recognized as a source of carvacrol and thymol.
Accessions of oregano vary widely in the amounts of carvacrol and thymol produced by the plants. Our research has shown that some accessions produce carvacrol predominantly over thymol while other accessions produce thymol predominantly over carvacrol. Conventional plant breeding techniques were used to produce clonal lines of oregano that had greater than 20 mg/g carvacrol, at 50 mg/g and up to at least 69.7 g/mg carvacrol on a dry matter basis. These high carvacrol lines typically had low levels of thymol, ranging from between a ratio of carvacrol to thymol of 10: 1, 50: 1 and up to at least 713: 1. In addition, conventional plant breeding techniques were used to produce clonal lines of oregano that had greater than 7 mg/g thymol, at 30 mg/g and up to at least 38.5 g/mg thymol on a dry matter basis. These high thymol lines typically had low levels of carvacrol, ranging from between a ratio of thymol to carvacrol of 5: 1, 10: 1 and up to at least 49.7: 1.
[0013] Inhibitory levels were first determined using carvacrol and thymol standards.
Subsequently, the HC:HT oils extracted from plants grown internally were blended achieving the targeted levels of carvacrol and thymol. Further inhibition assays were conducted to verify the effectiveness of the oil blend.
[0014] Standards. Thymol and carvacrol were purchased from Sigma- Aldrich Chemical
Company.
[0015] Oregano oil. The oregano oil used in these experiments was extracted from plants grown internally. Plant lines containing high carvacrol levels (HC) were identified. Specifically, the hich carvacrol strain KI-Ovl750, which is the subject of United States Patent Application Serial No. 61/855,067, filed May 7, 2013 (which is incorporated herein in its entirety by this reference), was developed. The oil extracted from the HC plant lines was combined and resulted in a carvacrol level of 67.7% (thymol level of 0.93%). Plant lines containing high thymol levels (HT) were identified. Specifically, the high thymol strain KI-Ovl850, which is the subject of United States Patent Application Serial No. 61/855,068, filed May 7, 2013 (which is
incorporated herein in its entirety by this reference), was developed. The oil extracted from HT oregano plant lines plant lines resulted in a thymol level of 70% (carvacrol level of 8.3%). [0016] Microbial cultures. Stock cultures of Escherichia coli 413-1, ATCC 25922, Salmonella Enteritidis, ATCC 13076, Bacillus subtilis PB6 (Kemin Industries) and Lactobacillus johnsonii Dl 15 (Kemin Industries) were cultured from agar plates held at 4 °C and inoculated into tubes of either Tryptic Soy Broth (TSB) or de Man, Rogosa and Sharpe (MRS) broth. The bacteria were incubated aerobically or anaerobically as appropriate at 37 °C for 20-22 h. All microbial cultures used in this work are strains maintained in an in-house culture collection.
[0017] Treatment Preparation - standards (Tables 1 and 2). Stock solutions of 1000 ppm each of carvacrol and thymol standards were prepared in sterile TSB to which 0.1% agar was added for stabilization of the oil: water emulsion (Rasooli et al., 2007; Burt, S. and R. Reinders. 2003. Antibacterial activity of selected plant essential oils against Escherichia coli 0157:H7. Letters Appl. Microbiol. 36: 162-167). Subsequent dilutions and/or combinations of the standard stock solutions were prepared in TSB to achieve the targeted inclusion level of each molecule.
[0018] Treatment Preparation - extracted oils (Tables 3 and 4). Stock solutions of 1000 ppm were made of each of the HC and HT extracted oils in sterile TSB or MRS broth to which 0.1% agar was added. Subsequent dilutions and/or combinations of the extracted oil stock solutions were prepared in TSB or MRS to achieve the targeted inclusion level of each molecule.
[0019] Blended oils. The extracted oils were blended in a 2: 1 ratio (v/v) of HC:HT.
[0020] Treated Agar Assay. Liquid Mueller Hinton agar was treated with the blended oil achieving treatment levels of 0.02% to 0.5% (200-5000 ppm) and allowed to solidify. A 0.5 mL aliquot of either E. coli or S. Enteritidis was inoculated onto the surface of separate plates and allowed to dry at room temperature under laminar flow. All plates were refrigerated 2 h followed by aerobic incubation at 37 °C for 20 h. The plates were not sealed. Visual
observations were made to determine if growth was present at a specific treatment level.
[0021] Microtiter Plate Assay. The efficacy of carvacrol and thymol in the inhibition of microbial growth was evaluated in a microtiter plate assay measuring the optical density at 620 nm using an Optimax microtiter plate reader (Molecular Devices, Sunnyvale, CA). Plates were read kinetically (aerobic organisms) or endpoint (anaerobic organisms) over 20-24 h while maintaining temperature at 35 °C. All results reflect the average optical density measurements of four microtiter wells. A 100 uL aliquot of a test organism (1.0E+06 cfu/mL) in sterile saline and a 100 μΐ^ aliquot of experimental treatment were dispensed into individual microtiter plate wells. Treatments prepared in TSB were used for E. coli, S. Enteritidis and PB6 while treatments prepared in MRS broth were used for L. johnsonii Dl 15. Positive controls consisted of 100 μΐ^ of test organism in sterile saline and 100 μΐ^ of sterile TSB or MRS. Negative controls were made of 100 μΐ^ of sterile TSB or MRS and 100 μΐ^ of sterile saline (no organisms).
[0022] Treatments. The inhibitory levels of carvacrol and thymol against selected
microorganisms were evaluated through several formulation matrices designed to assess the individual molecules as well as combinations of the molecules. Initially, thirteen formulations were prepared according to the incomplete 4x4 matrix design in Table 1 using 0, 125, 250 and 500 ppm each of carvacrol standard and thymol standard to evaluate the inhibitory activity toward selected microorganisms. In all instances formulas are noted as Fl, F2, etc. Subsequent matrices were designed to fine-tune inclusion levels of carvacrol and thymol.
Table 1. A 4x4 matrix design of 13 combinations of carvacrol standard (98%) and thymol standard (99.5%)
Carvacrol (ppm)
0 125 250 500
0 Fl F2 F3 F4
Thymol 125 F5 F6 F7 F8
(ppm) 250 F9 F10 Fl l F12
500 F13 NA NA NA
[0023] A second incomplete 4x4 matrix of 15 formulations (Table 2) was created to evaluate the inhibition of selected microorganisms using reduced levels of carvacrol standard and thymol standard.
Table 2. A 4x4 matrix design of 16 combinations of carvacrol standard (98%) and thymol standard (99.5%) at reduced levels based on assays results from Table 1
Carvacrol (ppm)
0 31.25 62.5 125
0 Fl F2 F3 F4
Thymol 31.25 F5 F6 F7 F8
(ppm) 62.5 F9 F10 Fl l F12
125 F13 F14 F15 F16 [0024] A third matrix of 9 formulas (Table 3) was created using oil from oregano plants grown by SCI and extracted on site. The treatment levels chosen were based on activity levels observed in previous experiments using carvacrol and thymol standards. For example, if 125 ppm of a 98% carvacrol standard was sufficient to inhibit the growth of a selected bacteria, then 180 ppm of extracted oil containing 68% carvacrol would be required to observe the same effect.
Table 3. A 3x3 matrix design of 9 combinations using oil extracted from oregano plants harvested by SCI. The HC oregano plants contained 68% carvacrol while the HT oregano plants contained 70% thymol
HC oil (ppm)
0 100 200
0 Fl F2 F3
HT
oil 100 F4 F5 F6
(ppm)
200 F7 F8 F9
[0025] A fourth matrix of 9 formulations was prepared using SCI oregano oil of 68% carvacrol but supplemented with carvacrol standard to achieve an 80% carvacrol level. The HT oil was used as extracted. Treatment levels were targeted based on previous results.
Table 4. A 3x3 matrix design of 9 formulations using oil extracted from SCI oregano plants where the HC oil was supplemented with carvacrol standard to achieve an 80% carvacrol level
HC oil (ppm)
0 87.5 175
0 Fl F2 F3
HT
oil 87.5 F4 F5 F6
(ppm)
175 F7 F8 F9
RESULTS
[0026] The initial assays using treatment levels in Table 1 showed that >125 ppm but < 250 ppm of either carvacrol (C) or thymol (T) was needed to completely inhibit the growth of gram negative bacteria S. Enteritidis and E. coli in microtiter assays (Figs. 1A and IB). However, a carvacrohthymol ratio (C:T) of 125 ppm carvacrol to 125 ppm thymol (F6, Table 1) was adequate to inhibit the growth of both organisms. B. subtilis PB6 was more affected by treatment and growth was inhibited by either 125 ppm carvacrol (F2, Table 1) or 125 ppm thymol (F5, Table 1) (Fig. 1C).
[0027] Treatment levels of carvacrol and thymol below 125 ppm (Figs. 2A and 2B) showed clear treatment effects. Neither treatment of carvacrol at 125 ppm (F4, Table 2) nor treatment of thymol of 125 ppm (F13, Table 2) was sufficient to inhibit the growth of S. Enteritidis or PB6. However, the addition of 62.5 ppm thymol - resulting in a C:T ratio of 125:62.5 (F12, Table 2) - inhibited growth of S. Enteritidis while a C:T ratio of 125:31.25 (F8, Table 2) inhibited the growth of PB6. Similarly, carvacrohthymol ratios of 62.5: 125 (F15, Table 2) and 31.25: 125 (F14, Table 2) were sufficient to inhibit the growth of S. Enteritidis and PB6, respectively. In this experiment, endpoint measurements were used due to the number of treatments involved and multiple plates being required.
[0028] The inhibitory effects of the oregano oil extracted from plants grown by SCI were evaluated. In this experiment, both carvacrol and thymol levels in the extracted oils were normalized to the standards to observe any further benefits the extracted oil contributed to overall microbial inhibition. For example, 125 ppm of a 98% carvacrol standard was needed to achieve inhibition when combined with thymol; therefore, 180 ppm of the 68% high carvacrol oil was used in the matrix formulations (Figs. 3 A and 3B).
[0029] The carvacrol level in the SCI extracted oil was increased from 68% to 80% using carvacrol standard and verified via HPLC analysis. The thymol level in the extracted oil was maintained at 70%. Using the results previously achieved with carvacrol included at different levels, treatment levels were selected and inhibition of microorganisms was evaluated.
[0030] Figs. 4A-4D are charts showing the kinetic growth curves showing the effects of treatment -HC, HT or HC:HT oils - using oregano oil extracted from plants grown by SCI. The level of carvacrol in the extracted HC oil was increased to 80%. The effects to the growth of S. Enteritidis and L. johnsonii Dl 15 are shown in graphs A and B, respectively. Graphs C and D reflect the effect of treatment on E. coli. One well in each of series F5 and F7 showed growth and could have been inadvertent contamination or variability in the inoculum used in the wells. Graph C includes the readings from all 4 wells while graph D does not include the well with growth. While there is minimal difference, this could be indicative of the "borderline" treatment level of F5.
[0031] Oregano oil at treatment levels above 500 ppm interfered with the optical density readings of the microtiter plate assay resulting in negative OD values. To observe the effect on microbial growth at the higher levels of the blended oils, a treated agar assay was conducted and evaluated for growth/no growth. While previous microtiter screenings had shown that 300 ppm of the blended oils was effective in E. coli and S. Enteritidis inhibition, a wide range of treatment levels was evaluated.
Table 5. Effect of oregano oil blended at a 2: 1 ratio (HC:HT) on the growth of E. coli and S.
Enteritidis. The carvacrol level is 68%.
Treatment Treatment Level of Level of S.
Level Level Carvacrol Thymol E. coli Enteri¬
(ppm) (kg/T) (ppm) (ppm) tidis
0 0 0 0 Positive Positive
200 0.2 90 46 Positive Positive
500 0.5 225 115 Negative Negative
1000 1.0 450 230 Negative Negative
5000 5.0 2250 1150 Negative Negative
DISCUSSION
[0032] There are a number of commercially available products containing oregano oil on the market today. However, one has not been found that is marketed to contain high levels of both carvacrol and thymol. The HC and HT oregano oils provided by SCI were tested individually and in combinations to determine the MICs for two foodborne pathogens. The levels found to be inhibitive to S. Enteritidis and E. coli (Fig. 2) were similar to those reported in the literature in similar type assays (Sokovic, et al., 2007; Bajpai, et al., 2011; Ait-Ouazzou, A., L. Cherrat, L. Espina, S. Loran, C. Rota and R. Pagan. 2011. The antimicrobial activity of hydrophobic essential oil constituents acting alone or in combined processes of food preservation. Innovative Food Science and Emerging Technologies. 12:320-329). Animal feeding studies will be conducted to determine if these levels are suitable as determined by animal acceptance, improvements in targeted production parameters and overall cost of the treatment.
[0033] Carvacrol and thymol were found to be equally effective in the inhibition of E. coli and S. Enteritidis at the levels tested. As expected, higher concentrations of either of these molecules resulted in lower effective treatment levels. The absolute endpoint for efficacy of each molecule was not determined as the focus was to determine the lowest inclusion levels of each molecule in a blended product. The blended oils showed the most efficacy at a 2: 1 HC oil:HT oil or HT oil: HC oil ratio. This was also observed when using carvacrol and thymol standards. Carvacrol and thymol are structural isomers displaying similar inhibitory activity (Michiels, et al., 2007). It has been reported that the effects of carvacrol and thymol were additive in their inhibitory activity (Burt, S., R. Vlielander, H. Haagsman and E. Veldhuizen. 2005. Increase in activity of essential oil components carvacrol and thymol against Escherichia coli 0157.H7 by addition of food stabilizers. J. Food Protection 68(5):919-926). Because the level of carvacrol and thymol and other potentially bioactive components differ with oregano plant line, time of harvest, conditions of oil extraction, etc., it is important to determine the levels present in each batch of oil extracted. Table 6 highlights the different MICs based on different levels of carvacrol and thymol resulting from the experiments conducted. A carvacrol level of 80% was included for two reasons: 1) a major competitor markets an oregano oil product containing 80% carvacrol, and 2) it was of interest to observe the effect to treatment levels at a point between the standards and the SCI oil as extracted.
Table 6. Inhibitory C:T combinations (ppm) with varying concentrations of carvacrol and thymol from either standard solutions or extracted oils against G(-) and G(+) bacteria. The inhibitory C:T ratio of SCI oils reflect the adjustment to lower carvacrol and thymol levels in the oils compared to standard solutions.
Inhibitory C:T levels (ppm)
S. L.
Treatment Source E. coli PB6
Enteritidis johnsonii
98%
125:62.5 125:62.5 125:31.25 carvacrol Sigma- or or ND or 99.5% Aldrich
62.5: 125 62.5: 125 31.25: 125 thymol
80%
carvacrol
175:87.5 175:87.5
(adjusted
SCI oils or or >175:>175 ND w/std)
87.5: 175 87.5: 175
70%
thymol
68%
200: 100 200: 100
carvacrol
SCI oils or or ND 100: 100 70%
100:200 100:200
thymol
[0034] Generally G(+) organisms are more sensitive to the inhibitory effects of essential oils (Sokovic, et al., 2007; Guarda, et al., 2011; Ait-Ouazzou, et al., 2011; Ivanovic, J., D. Misic, I. Zizovic and M. Ristic. 2012. In vitro control of multiplication of some food-associated bacteria by thyme, rosemary and sage isolates. Food Control 25: 110- 116). This is supported by the C:T ratio of 125:31.25 ppm for PB6 (G+) observed in this work. As noted in Table 6, the C:T ratios for E. coli (G-) and S. Enteritidis (G-) are higher than that for B. subtilis PB6 (G+). Gram (-) organisms are more tolerant due to the hydrophilic outer membrane which blocks entry of the hydrophobic essential oil (Ait-Ouazzou, et al., 2011). Bacillus species were especially sensitive to thyme essential oil (Ait-Ouazzou, et al., 2011). While 125 ppm inhibited the growth of PB6 as noted in Fig 1, it was not sufficient to inhibit growth as noted in Fig 2. This may be indicative of a borderline treatment effect. Work conducted by J. Michiels, et.al reported that carvacrol and thymol inhibited the growth of E. coli and Lactobacillus similarly while work by Mathlouthi, et al. found Lactobacillus not sensitive to essential oils (Mathlouthi, N. T. Bouzaienne, I. Oueslati, F. Recoquillay, M. Hamdi, M. Urdaci and R. Bergaoui. 2011. Use of rosemary, oregano, and commercial blend of essential oils in broiler chickens: in vitro antimicrobial activities and effects on growth performance J. Anim. Sci. 2012. 90:813-823). In the experiments conducted here, L. johnsonii was less sensitive to the effects of treatment than was E. coli. As noted in Mathlouthi' s publication, differences in results are often observed and can be attributed to differences in microbial strains, methodologies, concentration of active compounds, etc.
[0035] As noted earlier, higher levels of the essential oil blend interfered with the OD readings of the microtiter assay necessitating an alternate methodology. The agar plate assay (Table 5) compared nicely with the microtiter assay in this work. The agar plate assay indicated that >200 ppm but <500 ppm of a 2: 1 HC:HT blended oil product (68% carvacrol and 70% thymol) would inhibit the growth of E. coli and S. Enteritidis. The microtiter assay (Table 6) resulted in 300 ppm of the same blend being the best level for growth inhibition. It was impossible not to detect the odor of oregano oil in the laboratory. While the agar plates were not sealed during
incubation, the microtiter plates were. Effective treatment levels were comparable.
[0036] In addition to the documented antimicrobial activity of oregano oil, this essential oil has also been cited in the literature to have anti-coccidial effects in broilers as well as indications that carvacrol and thymol may play a role in the inhibition of biofilm formation (Tsinas, A., II Giannenas, C. Voidarou, A. Tzora and J. Skoufos. 2011. Effects of an oregano based dietary supplement on performance of broiler chickens experimentally infected with Eimeria Acervulina and Eimeria Maxima. J. Poult. Sci. 48: 194-200; Giannenas, I., P. Florou-Paneri, M.
Papazahariadou, E. Christaki, N.A. Botsoglou and A.B. Spais. 2003. Effect of dietary
supplementation with oregano essential oil on performance of broilers after experimental infection with Eimeria Tenella. Arch. Anim. Nutr. 57(2):99-106; Soumya, E., I. Saad, L. Hassan, Z. Ghizlane, M. Hind and R. Adnane. 2011. Carvacrol and thymol components inhibiting Pseudomonas aeruginosa adherence and biofilm formation. African J. of Microbiol Res.
5(20):3229-3232).
[0037] The oregano oil available on the market today typically contains >60% carvacrol but thymol levels are 4% or less. A blended oil product containing high levels of both carvacrol and thymol will provide an additional "hurdle" for the pathogens to overcome.
[0038] The foregoing description and drawings comprise illustrative embodiments of the present inventions. The foregoing embodiments and the methods described herein may vary based on the ability, experience, and preference of those skilled in the art. Merely listing the steps of the method in a certain order does not constitute any limitation on the order of the steps of the method. The foregoing description and drawings merely explain and illustrate the invention, and the invention is not limited thereto, except insofar as the claims are so limited. Those skilled in the art whom have the disclosure before them will be able to make modifications and variations therein without departing from the scope of the invention.

Claims

We claim:
1. A blend of plant extracts, comprising a combined amount of carvacrol and thymol that is more effective as an antimicrobial than an equivalent amount of carvacrol alone or thymol alone.
2. A blend of extracts as defined in claim 1, wherein the ratio of carvacrol to thymol is between 1:4 and 4: 1.
3. A blend of extracts as defined in claim 2, wherein the ratio of carvacrol to thymol is between 1:3 and 3: 1.
4. A blend of extracts as defined in claim 3, wherein the ratio of carvacrol to thymol is between 1:2 and 2: 1.
5. A blend of extracts as defined in claim 1, wherein the ratio of carvacrol to thymol is between 1.5: 1 and 1:2.5.
6. A blend of extracts as defined in claim 1, wherein the ratio of carvacrol to thymol is between 1: 1.5 and 2.5: 1.
7. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant that contains not less than 20 mg/g carvacrol on a dry matter basis.
8. A blend of extracts as defined in claim 7, wherein said carvacrol is obtained from an oregano plant that contains not less than 50 mg/g carvacrol on a dry matter basis.
9. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant that has a ratio of carvacrol to thymol of at least 10: 1.
10. A blend of extracts as defined in claim 9, wherein said carvacrol is obtained from an oregano plant that has a ratio of carvacrol to thymol of at least 50: 1.
11. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant of the line KI-Ovl750.
12. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant that contains not less than 7 mg/g carvacrol on a dry matter basis.
13. A blend of extracts as defined in claim 12, wherein said carvacrol is obtained from an oregano plant that contains not less than 30 mg/g carvacrol on a dry matter basis.
14. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant that has a ratio of carvacrol to thymol of at least 5: 1.
15. A blend of extracts as defined in claim 14, wherein said carvacrol is obtained from an oregano plant that has a ratio of carvacrol to thymol of at least 10: 1.
11. A blend of extracts as defined in claim 1, wherein said carvacrol is obtained from an oregano plant of the line KI-Ovl850.
PCT/US2014/037148 2013-05-07 2014-05-07 Antimicrobial compositions containing carvacrol and thymol Ceased WO2014182813A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201480026108.6A CN105357971A (en) 2013-05-07 2014-05-07 Antimicrobial compositions containing carvacrol and thymol
EP14794324.5A EP2993985A4 (en) 2013-05-07 2014-05-07 Antimicrobial compositions containing carvacrol and thymol
BR112015027837A BR112015027837A2 (en) 2013-05-07 2014-05-07 COMBINATION OF PLANT EXTRACTS USED AS A FEED ADDITIVE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361820455P 2013-05-07 2013-05-07
US61/820,455 2013-05-07

Publications (1)

Publication Number Publication Date
WO2014182813A1 true WO2014182813A1 (en) 2014-11-13

Family

ID=51865240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/037148 Ceased WO2014182813A1 (en) 2013-05-07 2014-05-07 Antimicrobial compositions containing carvacrol and thymol

Country Status (5)

Country Link
US (2) US20140336271A1 (en)
EP (1) EP2993985A4 (en)
CN (1) CN105357971A (en)
BR (1) BR112015027837A2 (en)
WO (1) WO2014182813A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102037066B1 (en) * 2017-10-31 2019-10-29 부산대학교 산학협력단 A Composition for Sterilization Containing Thymol and Carvacrol, Composition for Purification Ballast Water Containing the Same and Method with the Same for Purifying Ballast Water
CN111183991A (en) * 2020-03-03 2020-05-22 安徽金敦福农业科技有限公司 Thymol-containing pesticide composition
MX2023006676A (en) 2020-12-09 2023-07-04 Purina Animal Nutrition Llc Feed compositions and methods for inhibiting focal ulcerative dermatitis.
CN114903059A (en) * 2022-06-21 2022-08-16 广东省农业科学院植物保护研究所 Thymus vulgaris oil and application of preparation thereof in preventing and treating crop soft rot

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069277A1 (en) * 1999-05-12 2000-11-23 Akzo Nobel Nv A composition containing carvacrol and thymol for use as a bactericide
WO2011119047A1 (en) * 2010-03-26 2011-09-29 Ewos Innovation As Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186250B1 (en) * 1995-05-26 2003-12-31 Ropapharm Bv Pharmaceutic composition based on etheral oils obtained from plants for use in the field of human and animal medicine
GR1002451B (en) * 1995-06-29 1996-10-14 ������ �. Anti-inflamatory compositions containing herbal-based active ingredients, methods of preparing same and uses of same for medical and veterinary purposes.
ATE253904T1 (en) * 1997-09-30 2003-11-15 Ropapharm B V USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING THYMOL AND/OR CARVACROL IN THE TREATMENT OF HISTOMONIASIS
US5965518A (en) * 1998-02-23 1999-10-12 Nakatsu; Tetsuo Fragrance compositions having antimicrobial activity
US6110888A (en) * 1999-05-10 2000-08-29 Takasago International Corporation Substituted phenols as fragrance, flavor and antimicrobial compounds
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US6921539B2 (en) * 2002-02-20 2005-07-26 Dusan Ninkov Antimicrobial therapeutic compositions and method of use
DK1656026T3 (en) * 2003-08-22 2014-07-14 Dupont Nutrition Biosci Aps COMPOSITION CONTAINING A BACTERIOCIN AND AN EXTRACT FROM A PLANT OF THE LIP FLOWER FAMILY
US8017667B2 (en) * 2004-06-29 2011-09-13 Victoria University Antimicrobial packaging material
DE102004049574A1 (en) * 2004-10-12 2006-04-20 Doris Dr. Barnikol-Keuten Drugs and System for Percutaneous Drug Delivery
US8119169B2 (en) * 2004-12-28 2012-02-21 Colgate-Palmolive Company Oregano oral care compositions and methods of use thereof
WO2006120494A1 (en) * 2005-05-13 2006-11-16 Advanced Scientific Developements Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
PL2348838T3 (en) * 2008-10-20 2013-10-31 Unilever Nv An antimicrobial composition
EP2451468B1 (en) * 2009-07-08 2017-01-11 Onikolabs LLC Topical antifungal composition
FR2956814B1 (en) * 2010-02-26 2020-11-20 Oreal USE OF ORIGAN OR ROSEWOOD ESSENTIAL OIL, OR THEIR CONSTITUENTS, IN THE COSMETIC TREATMENT OF KERATOSES
US20130224125A1 (en) * 2010-08-03 2013-08-29 Narayanan S. Kolazi Alcohol-free slightly-alcoholic oral care composition and a process for preparing same
US10821085B2 (en) * 2010-12-07 2020-11-03 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical composition having antimicrobial properties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069277A1 (en) * 1999-05-12 2000-11-23 Akzo Nobel Nv A composition containing carvacrol and thymol for use as a bactericide
WO2011119047A1 (en) * 2010-03-26 2011-09-29 Ewos Innovation As Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"SRA065908 DRA search", 30 January 2013 (2013-01-30), pages 1, XP008185905, Retrieved from the Internet <URL:https://trace.ddbj.nig.ac.jp/DRASearch> [retrieved on 20140812] *
D' ANTUONO ET AL.: "Variability of essential oil content and composition of Origanum vulgare L. populations from a north mediterranean area (Liguria region, northern Italy", ANNALS OF BOTANY., vol. 86, no. 3., 2000, pages 471 - 478, XP055294295 *
GOLIARIS ET AL.: "Production of new Greek Oregano clones and analysis of their essential oils.", JOURNAL OF HERBS, SPICES & MEDICINAL PLANTS., vol. 10, no. 1., January 2002 (2002-01-01), pages 29 - 35, XP055294296 *
See also references of EP2993985A4 *

Also Published As

Publication number Publication date
CN105357971A (en) 2016-02-24
EP2993985A1 (en) 2016-03-16
EP2993985A4 (en) 2016-10-05
BR112015027837A2 (en) 2017-08-29
US20140336271A1 (en) 2014-11-13
US20160157482A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
Rattanachaikunsopon et al. Assessment of factors influencing antimicrobial activity of carvacrol and cymene against Vibrio cholerae in food
Abdollahzadeh et al. Antibacterial activity of plant essential oils and extracts: The role of thyme essential oil, nisin, and their combination to control Listeria monocytogenes inoculated in minced fish meat
Abdoul-Latif et al. Antimicrobial and antioxidant activities of essential oil and methanol extract of Matricaria chamomilla L. from Djibouti
Barros et al. Combination of Origanum vulgare L. essential oil and lactic acid to inhibit Staphylococcus aureus in meat broth and meat model
KR101806130B1 (en) Antimicrobial and antioxidant composition comprising active components from fermented powder of lactic acid bacteria and herb extract for meat products
Abdaslam et al. Isolation of Escherichia coli O157 and other food borne pathogens from meat products and their susceptibility to different antimicrobial agents
Angienda et al. Potential application of plant essential oils at sub-lethal concentrations under extrinsic conditions that enhance their antimicrobial effectiveness against pathogenic bacteria
Kamona et al. Effect of essential oil extract from lemongrass (Cymbopogon citratus) leaves on vaiability of some pathogenic bacteria and sensory properties of fish balls
US20160157482A1 (en) Antimicrobial Compositions Containing Carvacrol and Thymol
Dua et al. Methanol extract of clove (Syzygium aromaticum Linn.) damages cells and inhibits growth of enteropathogens
Jovanka et al. In vitro antibacterial activity of essential oils from plant family Lamiaceae
Petrová et al. Microbiological Quality of Fresh Chicken Breast Meat after Rosemary Essential Oil Treatment and Vacuum Packaging.
KR20110120394A (en) Antimicrobial Composition Extracted from Chrysanthemum Flowers
Suarez M et al. Determination of microbiological and sensoryparameters of fish fillets with propolis preserved under refrigeration
Liu et al. Antimicrobial activities of olive leaf extract and its potential use in food industry
Cabarkapa et al. Antimicrobial activity of Origanum heracleoticum L. essential oil from Serbia
CN109805242B (en) Composite plant extract, preparation method and application
KR20200045569A (en) Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prohylactic use or treatment of salmonella infection
Angienda et al. The effect of sodium chloride and pH on the antimicrobial effectiveness of essential oils against pathogenic and food spoilage bacteria: implications in food safety
Kalaba et al. COMPARATIVE EFFECTS OF ESSENTIAL OILS ON GROWTH OF Escherichia coli.
Dikici et al. Effects of essential oil compounds on survival of Listeria monocytogenes and Escherichia coli O157: H7 in çiğ köfte
Saleh et al. Antibacterial and anti-oxidant activities of laurel oil against Staphylococcus aureus and Pseudomonas fluorescence in Oreochromis niloticus fillets
Aykut et al. Antimicrobial activity of a novel biodegradable edible film produced from Pistacia vera resin and Origanum vulgare essential oil. Res
KR102707967B1 (en) Synergistic antimicrobial effect between rosemary extract, cultured dextrose and buffered vinegar
Kačániová et al. Effect of Thymus serpyllum and Ocimum basilicum essential oils on the shelf-life of chicken’s meat during refrigerated storage

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480026108.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14794324

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014794324

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015027837

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015027837

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151104